Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.)
- PMID: 1921242
- DOI: 10.1007/BF01647413
Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.)
Abstract
Lymphocytes of 25 patients treated with an aqueous mistletoe extract (Viscum album L.) for up to 6 months (group 1), up to 2 years (group 2), and more than 2 years (group 3) were examined in 3- and 7-day cultures for specifically sensitized lymphocytes. The whole extract (HM), the lectin-polysaccharide fraction (HM-LP), and the 'viscotoxin' fraction (HM-V) were added at concentrations ranging from 0.5 micrograms to 12.5 mg extract/ml. Lymphocytes from four of the nine group 2 patients and five of the ten group 3 patients reacted specifically with HM and HM-LP at an optimal dose of 5.0 mg/ml, but did not react with HM-V. Stimulation indices varied between 1.6 and 16. In the patients of group 3 this effect was observed only when their lymphocytes were co-stimulated in the 3-day cultures with phytohemagglutinin (PHA), in contrast to the four patients of group 2 who reacted only in the 7-day cultures with HM-LP without PHA co-stimulation. Patients' lymphocytes had to be protected from mistletoe lectin-induced cytotoxicity by the addition of their own sera containing anti-mistletoe lectin antibodies. Lymphocytes from tumor patients (n = 18) never treated with mistletoe extracts and healthy individuals (n = 18) showed no specific proliferative response when tested in 3- and 7-day cultures.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro.Klin Wochenschr. 1990 Sep 14;68(18):896-900. doi: 10.1007/BF01649034. Klin Wochenschr. 1990. PMID: 2124308
-
In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.Eur J Med Res. 2002 Apr 30;7(4):155-63. Eur J Med Res. 2002. PMID: 12010650 Clinical Trial.
-
Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins.Cancer Lett. 1996 Jan 19;99(1):59-72. doi: 10.1016/0304-3835(95)04038-2. Cancer Lett. 1996. PMID: 8564930
-
Differences in the apoptosis-inducing properties of Viscum album L. extracts.Anticancer Drugs. 1997 Apr;8 Suppl 1:S9-14. doi: 10.1097/00001813-199704001-00003. Anticancer Drugs. 1997. PMID: 9179360 Review.
-
[Mistletoe therapy from the pharmacologic perspective].Forsch Komplementarmed. 1999 Aug;6(4):186-94. doi: 10.1159/000021248. Forsch Komplementarmed. 1999. PMID: 10529578 Review. German.
Cited by
-
The inhibitory effects of a positive inotropic quinolinone derivative, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), on bone-marrow progenitor cells and peripheral lymphocytes.Eur J Clin Pharmacol. 1992;42(6):629-33. doi: 10.1007/BF00265927. Eur J Clin Pharmacol. 1992. PMID: 1623903
-
Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells.Mol Cell Biochem. 2014 Sep;394(1-2):225-35. doi: 10.1007/s11010-014-2099-y. Epub 2014 May 31. Mol Cell Biochem. 2014. PMID: 24878989
-
Modulation of Breast Cancer Cell Apoptosis and Macrophage Polarization by Mistletoe Lectin in 2D and 3D Models.Int J Mol Sci. 2024 Aug 2;25(15):8459. doi: 10.3390/ijms25158459. Int J Mol Sci. 2024. PMID: 39126027 Free PMC article.
-
Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.Br J Cancer. 2004 Jan 12;90(1):65-9. doi: 10.1038/sj.bjc.6601463. Br J Cancer. 2004. PMID: 14710208 Free PMC article. Clinical Trial.
-
Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.Eur J Clin Pharmacol. 1994;47(1):33-8. doi: 10.1007/BF00193475. Eur J Clin Pharmacol. 1994. PMID: 7988621